ImmunoBiochem Corp.

ImmunoBiochem Corporation is solving the problem of tumor heterogeneity by targeting a novel class of proteins in the tumor microenvironment with Antibody Drug Conjugates (ADCs) – a promising class of anticancer therapeutics that combine the selectivity of targeted biologics with the potency of highly cytotoxic small-molecule drugs.

Select cancer targets are only secreted by cancer cells and accumulate in tumors, and can be exploited for targeted and selective delivery of cytotoxic payloads with ImmunoBiochem’s engineered biological therapeutics.

Focus area
Oncology
Commencement date
11/08/2017